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Abstract 
 
Background: Previous research has demonstrated an association between anaemia 
and poor outcomes in acute stroke. This study aimed to assess the impact of anaemia 
on stroke by anaemia subtype.  
Methods: Data from a prospective UK Regional Stroke Register were used to assess 
the association between hypochromic microcytic and normochromic normocytic 
anaemia on inpatient-mortality, length of stay (LOS) and discharge modified Rankin 
scale (mRS). Analysis was stratified by stroke subtypes and multivariable logistic 
regression, adjusting for potential confounders, was used to quantify this association. 
Patients who were not anaemic were the reference category.  
Results: A total of 8,167 stroke patients (admitted between 2003 – 2015) were 
included, mean age (SD) 77.39 ± 11.90 years. Of these, 3.4% (n=281) had 
hypochromic microcytic anaemia and 15.5% (n=1,262) had normochromic 
normocytic anaemia on admission. Normochromic normocytic anaemia was 
associated with increased odds of in-patient mortality OR 1.48 (1.24 –1.77), 90-day 
mortality OR 1.63 (1.38 - 1.92), longer LOS OR 1.21 (1.06 – 1.40), defined as >7 
days, and severe disability defined as discharge mRS≥3 OR 1.31 (1.06 – 1.63), in 
patients with ischaemic stroke. Hypochromic microcytic anaemia was associated with 
90-day mortality OR 1.90 (1.40 – 2.58) and a longer LOS OR 1.57 (1.20 – 2.05) in 
patients with ischaemic stroke.  
Conclusions: Hypochromic microcytic and normochromic normocytic anaemia are 
associated with differing outcomes in terms of inpatient mortality and post stroke 
disability. While it is unclear if anaemia per se or another underlying cause is 
responsible for adverse outcomes, subtype of anaemia appears to be relevant in stroke 
prognosis. 
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1. Introduction 
The impact of comorbidities on stroke is an issue of increasing salience as the 
population continues to age. Anaemia is common among community-dwelling adults 
aged over 64 years [1] and has an estimated prevalence exceeding 20% in those aged 
over 84 years [2]. Anaemia is also relatively common among stroke patients and has a 
prevalence ranging from 15-30% [3]. A recent systematic review and meta-analysis 
has demonstrated an association between anaemia and poor outcomes subsequent to 
stroke [4]. Furthermore, anaemia has been shown to be associated with poor outcomes 
in other cardiovascular conditions such as heart failure [5] and acute coronary 
syndromes [6]. Finally, the presence of anaemia in patients with malignancy or 
chronic kidney disease also leads to poorer outcomes compared to those without 
anaemia [7, 8]. 
Following stroke adequate cerebral oxygenation is required to prevent further 
hypoxic cerebral damage. Adequate cerebral oxygenation depends on cerebral 
perfusion pressure, oxygen saturation and haemoglobin levels. Reduced haemoglobin 
levels are therefore thought to increase the severity of hypoxic injury resulting in 
poorer outcomes in stroke [3, 9]. However, anaemia is a heterogeneous condition and 
has several underlying pathological mechanisms. This is reflected morphologically 
between the different subgroups of anaemia, the two most common being 
normochromic normocytic and hypochromic microcytic anaemia, which are typically 
caused by chronic disease and iron deficiency, respectively [10].  
Differences in the aetiology of anaemia may influence the relationship 
between anaemia and adverse stroke outcomes. While previous research has shown an 
association between anaemia and poor acute stroke outcomes, the impact of the 
different subtypes of anaemia on stroke outcome has not been previously examined. 
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We therefore aimed to examine the association between anaemia type and in-patient 
mortality, 90-day mortality, length of hospital stay and disability outcome as indicated 
by the modified Rankin scale (mRS).  
 
2. Methods 
The study population of patients with acute stroke were drawn from a UK Regional 
Stroke register in the East Anglia Region, UK (with a catchment population of 
~750,000 people) during January 2003 to May 2015. The register received research 
database ethical approval form the Newcastle and Tyneside National Health Service 
(NHS) Research Ethics Committee (12/NE/0170) and the study protocol was 
approved by the Steering Committee of the Register. The data collection methods 
have previously been described [11]. Briefly, data was entered from paper and 
electronic records onto the stroke register database prospectively, under the 
supervision of a clinical team. Patients were included if they had a confirmed 
ischaemic or haemorrhagic stroke. This was ascertained by a clinical examination and 
neuroimaging results. Specialist stroke nurses ascertained the pre-stroke modified 
Rankin score (mRS) from medical records or discussion with relatives. The electronic 
database was linked up with other electronically held data on comorbidities and 
biochemistry data and the linkage of these data sources are updated annually. Linkage 
with the Office of National Statistics (ONS) for mortality data ensures near complete 
follow-up for this outcome.  
Variables for this study were chosen a priori using the literature to identify 
those shown to be associated with acute stroke mortality. These were age, sex, stroke 
type (ischaemic or haemorrhagic), pre-stroke disability mRS (0 – 5), Oxfordshire 
Community Stroke Project (OCSP) classification (Total Anterior Circulation Stroke, 
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Partial Anterior Circulation Stroke, Posterior Circulation Stroke, Lacunar Stroke), 
haemoglobin levels at admission, pre-stroke co-morbidities (Coronary Heart Disease, 
Congestive Heart Failure, Atrial Fibrillation, Hypertension, Hyperlipidaemia, 
Previous Stroke, Diabetes Mellitus, Peripheral Vascular Disease, Chronic Obstructive 
Pulmonary Disease, Chronic Kidney Disease, Falls, Malignancy, Dementia), prior use 
of antithrombotic drugs.  
The primary outcomes were inpatient and 90-day mortality. Secondary 
outcomes were longer length of stay (LOS) defined as > 7 days and poor composite 
functional and mortality outcome defined as discharge mRS 3-6. In-patient mortality 
status was assessed using the mortality status at discharge. Mortality at 90-days was 
derived using data acquired by linkage with the ONS, which specified date of death. 
The date of admission and discharge was recorded allowing the calculation of length 
of hospital stay. The exposure variables were two types of anaemia based on their 
microscopic appearance, namely, normochromic normocytic anaemia and 
hypochromic microcytic anaemia. These two types of anaemia were chosen as these 
are the most common types of anaemia in the elderly and thus there was a large 
enough power to study them. The World Health Organization’s criteria was used to 
define anaemia; anaemia was defined as Hb <12.0 g/dL in females and <13.0 g/dL in 
males [12].  Normochromic normocytic anaemia was defined as a Mean Corpuscular 
Volume (MCV) of 80 – 100 fL and a Mean Corpuscular Haemoglobin (MCH) of 27 – 
32 pg. Hypochromic microcytic anaemia was defined as a MCV of <27 and a MCH 
<80. Each type of anaemia was compared to the non-anaemic patients unless 
otherwise stated.  
The analyses were undertaken using SPSS Version 24.0 (SPSS Inc., Chicago, 
Illinois, USA). Chi-square tests were used to assess the differences between patient 
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characteristics, comorbidities and outcomes between the anaemic groups 
(hypochromic microcytic and normochromic normocytic anaemia) and the non-
anaemic group. Further Chi square tests were used to examine the differences in 
patient characteristics between each type of anaemia. The odds of having 
hypochromic microcytic or normochromic normocytic anaemia for each study 
outcome were assessed using logistic regression. For each outcome, the unadjusted 
and the fully adjusted models are presented. Adjustments were made for sex, age, 
Oxford Community Stroke Project (OCSP) classification, prior antithrombotic 
therapy status, stroke type, and co-morbidities listed above. In inpatient mortality, 
interactions between both types of anaemia and malignancy, chronic kidney disease 
and cardiovascular comorbidities were tested. The fully adjusted models were 
repeated for ischaemic and haemorrhagic stroke separately. A sensitivity analysis was 
completed examining the association between inpatient mortality and both types of 
anaemia stratified by level of comorbidity burden. All analyses used complete case 
analysis.  
 
3. Results 
Between January 2003 and May 2015 the registry recorded 11,886 patients were 
admitted to stroke services during the study period (911 episodes of stroke were 
excluded as they were a repeated event during the study period). After further 
exclusion of 3,719 patients that did not meet the study inclusion criteria (see Figure 
1), a total of 8,167 patients were included in the current study. The mean age (SD) of 
the sample was 77.4 ± 11.9 years of whom 46.9% were male, and 86.9% had 
ischaemic stroke. A majority of patients (64.3%) had a pre-stroke mRS of 0 and 
Partial Anterior Circulation Stroke (PACS (33.4%) was the most common subtype. 
Inpatient mortality for the sample population was 20.8% (N=1,696) and 
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approximately a fifth (18.9%) had anaemia on admission. The mean LOS was 13.8 
(SD ± 16.9) days. The mean haemoglobin (Hb) level was 13.7 (SD ± 1.8) for the 
whole population, 10.2 (SD ± 1.5) in those with hypochromic microcytic anaemia and 
11.3 (SD ± 1.1) in those with normochromic normocytic anaemia. Hypochromic 
microcytic anaemia was present in 3.4% (N=281) of patients and normochromic 
normocytic anaemia was present in 15.5% (N=1,262).  
 
Figure 1. Patient Inclusion Chart 
  
 
 
 
 
  
 
 
 
 
 
Table 1 illustrates the distribution of the sample characteristics according to 
anaemia status. The hypochromic microcytic anaemia group had a significantly higher 
proportion of females, those aged 81-90 years old, higher pre-stroke modified Rankin 
scores, higher proportions of ischaemic strokes, PACS and higher comorbidity burden 
than non-anaemic patients. However, there were non-significant differences in the 
prevalence of atrial fibrillation, chronic kidney disease and dementia. Furthermore, 
patients with hypochromic microcytic anaemia compared to those with patients with 
no anaemia had higher inpatient mortality rates, a higher proportion of patients whose 
hospital stay was longer than 7 days and 59.2% had a discharge Rankin score of 3-6, 
which were statistically significant.   
Exclusions: 
1,393 – other types of anemia 
991 - subsequent strokes in the same patient 
578 – missing data for OSCP classification 
544 – missing data for pre-morbid mRs 
207 – subarachnoid haemorrhage 
6 – below 18 years of age 
 
 
11,886 strokes on the register 
8,167 patients used as 
final sample population 
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Table 1. Study population characteristics by anaemia status compared to the non-anaemic group  
Variable No Anaemia Hypochromic 
Microcytic  
P-Value* Normochromic 
Normocytic  
P-
Value* 
P-
Value** 
Total 6,624 281  1,262   
Sex   0.001  <0.001 <0.001 
Female 3,563 (53.8) 180 (64.1)  589 (46.7)   
Male 3,061 (46.2) 101 (35.9)  673 (53.3)   
Age   <0.001  <0.001 0.338 
≤ 60 700 (10.6) 15 (5.3)  44 (3.5)   
61 – 70 1,095 (16.5) 23 (8.2)  86 (6.8)   
71 - 80 1,937 (29.2) 75 (26.7)  338 (26.8)   
81 - 90 2,318 (35.0) 126 (44.8)  630 (49.9)   
≥ 91 574 (8.7) 42 (6.8)  164 (13.0)   
Pre-stroke Rankin Score   <0.001  <0.001 0.825 
0 4,499 (67.9) 132 (47.0)  618 (49.0)   
1 729 (11.0) 40 (14.2)  193 (15.3)   
2 488 (7.4) 33 (11.7)  138 (10.9)   
3 530 (8.0) 43 (15.3)  176 (13.9)   
4 277 (4.2) 24 (8.5)  86 (6.8)   
5 101 (1.5) 9 (3.2)  51 (4.0)   
Stroke Type, n (%)   0.002  0.028  0.035 
Ischaemic 5,716 (86.3) 261 (92.9)  1,118 (88.6)   
Haemorrhagic      908 (13.7) 20 (7.1)  144 (11.4)   
Bamford Classification, n (%)   0.013  <0.001  0.174 
LACS 1,593 (24.0) 65 (23.1)  252 (20.0)   
PACS 2,202 (33.2) 103 (36.7)  421 (33.4)   
POCS 1,182 (17.8) 29 (10.3)  197 (15.6)   
TACS 1,301 (19.6) 65 (23.1)  301 (23.9)   
Undefined 346 (5.2) 19 (6.8)  91 (7.2)   
Prior Antithrombotic therapy   0.357  <0.001  0.108 
No 3,321 (50.1) 133 (47.3)  531 (42.1)   
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Yes 3,303 (49.9) 148 (52.7)  731 (57.9)   
Pre-stroke Comorbidity       
Stroke/TIA 1,568 (23.7) 75 (26.7) 0.244 372 (29.5) <0.001  0.352 
CHD/MI 962 (14.5) 59 (21.0) 0.004 351 (27.8) <0.001  0.019 
Congestive Heart Failure 395 (6.0) 34 (12.1) <0.001 176 (13.9) <0.001  0.414 
Hypertension 1,780 (26.9) 105 (37.4) <0.001 524 (41.5) <0.001  0.200 
Hyperlipidemia  240 (3.6) 17 (6.0) 0.035 66 (5.2) 0.007  0.582 
Atrial Fibrillation 1,916 (28.9) 90 (32.0) 0.262 428 (33.9) <0.001  0.545 
Diabetes Mellitus 499 (7.5) 45 (16.0) <0.001 210 (16.6) <0.001  0.798 
COPD 238 (3.6) 22 (7.8) <0.001 93 (7.4) <0.001  0.791 
Chronic Kidney Disease 107 (1.6) 8 (2.8) 0.114 100 (7.9) <0.001  0.003 
Malignancy 585 (8.8) 44 (15.7) <0.001 223 (17.7) <0.001  0.420 
Dementia 166 (2.5) 13 (4.6) 0.028 73 (5.8) <0.001  0.444 
Falls 764 (11.5) 72 (25.6) <0.001 257 (20.4) <0.001  0.052 
Inpatient Mortality   <0.001  <0.001  0.319 
Alive 5,400 (81.5) 202 (71.9)  869 (68.9)   
Dead 1,224 (18.5) 79 (28.1)   393 (31.1)   
Length of Stay (Days)   <0.001  <0.001  0.221 
1 – 7 3,252 (49.1) 104 (37.0)  517 (41.0)   
Over 7 Days 3,372 (50.9) 177 (63.0)  745 (59.0)   
Discharge Rankin Score***   <0.001  <0.001  0.262 
0 593 (17.4) 19 (11.7)  77 (11.4)   
1 674 (19.8) 25 (15.4)  88 (13.0)   
2 421 (12.3) 21 (13.0)  72 (10.7)   
3 513 (15.0) 19 (11.7)  120 (17.8)   
4 478 (14.0) 19 (11.7)  112 (16.6)   
5 207 (6.1) 12 (7.4)  39 (5.8)   
6 499 (14.6) 46 (28.4)  161 (23.9)   
*Test for difference between type of anaemia group and no anaemia group **Test for difference between microcytic and normocytic anaemia  
***n = 4,215 
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However, patients with normochromic normocytic anaemia compared to 
patients with no anaemia had a higher proportion of males, older aged patients, higher 
pre-stroke Rankin scores, higher proportions of ischaemic stroke, TACS type and 
higher burden of comorbidities, which were statistically significant at the 5% level. 
Table 1 also presents a comparison of patient characteristics between normochromic 
normocytic and hypochromic microcytic anaemia groups. Hypochromic microcytic 
anaemia had higher proportions of females, haemorrhagic strokes and previous 
coronary heart disease or myocardial infarction compared to normochromic 
normocytic anaemia. Normochromic normocytic anaemia was associated with a 
higher prevalence of CKD. 
Table 2 shows the univariable and multivariable logistic regression analysis 
results which examined the likelihood of inpatient mortality, 30-day mortality, 1-year 
mortality, longer length of stay (> 7 days) and a high discharge modified Rankin score 
of 3-6, in both normochromic normocytic and hypochromic microcytic compared to 
no anaemia. Results were stratified by stroke type (ischaemic/ haemorrhagic). In the 
unadjusted analysis, there was a significant association between all the acute 
outcomes and both anaemia subtypes compared to those without anaemia.  
After full adjusting for confounders, normochromic normocytic anaemia was 
associated with poorer outcomes in ischaemic stroke for every outcome under 
assessment. Odds ratios for inpatient mortality, 90-day mortality, long length of stay 
and high discharge Rankin score were; 1.48 (95% CI 1.24 – 1.77), 1.63 (95% CI 1.38 
– 1.92), 1.21 (95% CI 1.06 – 1.40) and 1.31 (95% CI 1.06 – 1.63) respectively. 
Hypochromic microcytic anaemia was also associated with higher odds of 90-day 
mortality and long length of stay with odds ratios of 1.90 (95% CI 1.40 - 2.58), and 
1.57 (95% CI 1.20 – 2.05). Regarding haemorrhagic stroke, neither sub-type of
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Table 2: Logistic regression models examining the association between types of anaemia and acute stroke outcomes 
 Unadjusted model Fully adjusted model* Ischaemic stroke only* Haemorrhagic stroke only* 
Inpatient Mortality 
No Anaemia 
Hypochromic Microcytic 
Normochromic Normocytic 
 
1.00 
1.73 (1.32 – 2.25) 
2.00 (1.74 – 2.28) 
 
1.00 
1.37 (0.99 – 1.89) 
1.42 (1.20 – 1.67) 
 
1.00 
1.37 (0.97 – 1.93) 
1.48 (1.24 – 1.77) 
 
1.00 
1.40 (0.52 – 3.81) 
1.23 (0.81 – 1.88) 
90-Day Mortality 
No Anaemia 
Hypochromic Microcytic 
Normochromic Normocytic 
 
1.00 
2.16 (1.69 – 2.77) 
2.19 (1.93 – 2.48) 
 
1.00 
1.90 (1.56 – 2.30) 
2.54 (2.05 – 3.15) 
 
1.00 
1.90 (1.40 – 2.58) 
1.63 (1.38 – 1.92) 
 
1.00 
1.01 (0.37 – 2.73) 
1.28 (0.84 – 1.94) 
Long Length of Stay † 
No Anaemia 
Hypochromic Microcytic  
Normochromic Normocytic  
 
1.00 
1.64 (1.28 – 2.10) 
1.39 (1.23 – 1.57) 
 
1.00 
1.41 (1.09 – 1.82) 
1.15 (1.02 – 1.33) 
 
1.00 
1.57 (1.20 – 2.05) 
1.21 (1.06 – 1.40) 
 
1.00 
0.48 (0.18 – 1.27) 
0.88 (0.59 – 1.30) 
Discharge Rankin Score‡ 
No Anaemia 
Hypochromic Microcytic  
Normochromic Normocytic 
 
1.00 
1.47 (1.07 – 2.03) 
1.81 (1.53 – 2.15) 
 
1.00 
1.09 (0.75 – 1.60) 
1.28 (1.04 – 1.57) 
 
1.00 
1.15 (0.78 – 1.70) 
1.31 (1.06 – 1.63) 
 
1.00 
0.53 (0.13 – 2.19) 
1.06 (0.53 – 2.11) 
*Adjusted for Sex, Age, OSCE Classification, Pre-Stroke Rankin Score, Stroke Type, Antithrombotic Therapy Status, Co-Morbidities (all of them). However, 
the ischaemic and haemorrhagic strokes only did not adjust for stroke type. 
† Over 7 days vs. Under 7 days. 
‡ Discharge modified Rankin Scale: 0 – 2 vs 3 - 6 
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anaemia was associated with worse outcomes.  
Table 3 depicted the association between anaemia subtype, comorbidity and 
odds of 90-day mortality in patients with ischaemic stroke, stratified by comorbidity 
burden. The magnitude of this association increases for those with over 3 
comorbidities compared to those with no comorbidities. However, the magnitude of 
association is slightly lower for those with 2-3 comorbidities compared to those with 
no comorbidities.  
 
4. Discussion 
To the knowledge of the authors, this is the first study to examine the relationship 
between anaemia and acute stroke outcomes by the specific morphological type of 
anaemia. Our retrospective analysis of a prospectively collected dataset observed that 
normochromic normocytic anaemia was associated with increased odds of inpatient 
mortality, 90-day mortality, longer length of stay and higher post-stroke disability in 
patients with ischaemic stroke. Furthermore, hypochromic microcytic anaemia was 
associated with increased odds of 90-day mortality and long length of stay in patients 
with ischaemic stroke. Neither sub-type of anaemia was associated with higher odds 
of poor outcomes in haemorrhagic stroke.  
Previous research has shown an association between anaemia, low 
haemoglobin and low haematocrit levels with poor outcomes in stroke [4, 13, 14]. 
However, no previous studies examined the relationship between the specific type of 
anaemia and stroke outcome. Our study illustrates that normochromic normocytic 
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Table 3. The association between 90-day mortality and anaemia status by level of comorbidity burden in ischaemic stroke 
No of 
comorbidities 
No anaemia Hypochromic 
microcytic 
Normocytic 
normochromic 
0 1.00 1.64 (0.89 – 3.00) 1.51 (1.15 – 2.25) 
1 1.00 1.47 (0.74 – 2.91) 1.49 (1.05 – 2.01) 
2-3 1.00 1.28 (0.61 – 2.21) 1.38 (1.03 – 2.21) 
Over 3 1.00 1.59 (0.82 – 3.07) 1.63 (1.11 – 2.17) 
Adjusted for: Age, Sex, OCSP Classification, Prior Antithrombotic Use and Pre-Stroke Modified Rankin Score. Included comorbidities: 
Coronary heart disease, congestive heart failure, atrial fibrillation, hypertension, hyperlipidaemia, previous stroke, diabetes mellitus, peripheral 
vascular disease, chronic obstructive pulmonary disease, chronic kidney disease, falls, malignancy and dementia 
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anaemia was associated with inpatient mortality, 90-day mortality, higher discharge disability 
score and longer length of stay. The pathogenesis of normochromic normocytic in these 
patients is likely to be the result of anaemia of chronic disease (ACD) [15, 16]. Previous 
research has shown that anaemia in patients with chronic heart disease was associated with 
longer length of hospital stay and mortality [17]. While this study was unable to typify the 
type of anaemia, the authors have stated that anaemia in chronic heart disease is mainly 
caused by ACD.  
Indeed, ACD is associated with a number of chronic diseases and is a common cause 
of anaemia in older individuals [18]. A number of biological mechanisms have been 
suggested for ACD. These include the detrimental effect of cytokines on haematopoiesis 
mediated by hepcidin [19] and the direct impact of ACE inhibitor medication [20]. However, 
the biological mechanisms linking normochromic normocytic anaemia and poor outcomes 
after an acute stroke event are not fully understood. Normochromic normocytic anaemia is 
itself the result of common medical comorbidities, which are independently associated with 
prognosis in elderly populations [21, 22]. We therefore attempted to evaluate the relationship 
between co-morbidity burden and increased odds of mortality in ischaemic stroke patients 
with normochromic normocytic anaemia. 
It was found that the relationship between normochromic normocytic anaemia and 
poor outcomes in ischaemic stroke persisted despite adjustment for multiple comorbidities 
(Table 2). On further analysis, the odds of inpatient mortality were slightly higher in those 
with over 3 morbidities compared to those with 1, in normochromic normocytic anaemia. 
However, the odds did not increase in a linear manner as the number co-morbidities increased 
(Table 3). It is possible that a higher number of comorbidities leads to increased frailty and 
this therefore explains the relationship between normochromic normocytic anaemia and 
worse outcomes in ischaemic stroke. However, the interaction between inflammation, 
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medical comorbidities and anaemia with poor stroke outcomes is complex and remains 
unknown. 
This study also found an association between hypochromic microcytic anaemia and 
higher odds of 90-day mortality, and long length of stay. Previous research has suggested that 
stroke patients with anaemia have a higher rate of complications [23].  This may therefore 
explain why both sub-types of anaemia are associated with longer length of stay in patients 
with ischemic stroke. We did not find an association between both anaemia types and poor 
outcomes in haemorrhagic stroke. Alternatively, haemorrhagic strokes are more likely to 
have poor outcomes so the effect of anaemia on outcomes may be minimal. Further research 
using a larger sample size is required to assess this association to eliminate the possibility of 
Type II error.  
Our study had some strengths. Due to a relatively large sample size, which enabled us 
to evaluate the association between acute stroke outcomes and specific subtypes of anaemia. 
We were also able to account for a large number of confounders in the analysis including 
numerous co-morbidities. Co-morbidity data was derived from the hospital Patient 
Administrative System (PAS) which records patient information based on referral letters 
(known diagnosis as described by the patients’ General Practitioner) and newly found 
diagnoses.  
Our study also had some limitations. Firstly, this study did not adjust for baseline 
NIHSS (National Institutes of Health Stroke Scale) score, as it was only available in <15% of 
the study population. However, the models contained age, stroke subtype, OSCP score and 
pre stroke Rankin score which are all shown to predict acute stroke outcomes, [24] the 
inclusion of the NIHSS would have only moderately improved the predictive ability of the 
model [25]. It is therefore unlikely that residual confounding from NIHSS substantially alters 
the findings within the current study. Secondly, a lack of statistical power may explain why 
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there was not an observed relationship between either anaemia sub-type and poor outcomes 
in intracerebral haemorrhage. Further studies, with a larger sample size are required in order 
to mitigate the chances of Type II error occurring. Finally, there was a substantial amount of 
missing data for the discharge modified Rankin score variable. However, this was because 
the NNUH Stroke Register began recording this variable in January 2009 and is therefore 
unlikely to lead to biased findings.  
As the population continues to age, the impact of comorbidities on patient outcomes 
is an issue of increasing salience. This cohort study demonstrated that both normochromic 
normocytic and hypochromic microcytic anaemia were associated with poor outcomes after a 
stroke event. Future trials are therefore required to gauge appropriate thresholds for 
transfusion in stroke patients with anaemia. Furthermore, clinicians may benefit from 
factoring in the impact of anaemia on stroke outcomes when prognosticating stroke patients. 
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Highlights  
 Normochromic normocytic anaemia was associated with higher post-stroke disability.  
 Hypochromic microcytic anaemia was associated with long length of stay.  
 Both sub-types of anaemia were associated with higher odds of mortality.  
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